Manufacturer of Controlled Substances; Notice of Registration; Nektar Therapeutics, 67677 [2012-27567]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 219 / Tuesday, November 13, 2012 / Notices
67677
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
prior to the meeting to Charlene
Williams.
[Notice 12–095]
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
NASA Advisory Council; Audit,
Finance and Analysis Committee;
Meeting
Patricia D. Rausch,
Advisory Committee Management Officer,
National Aeronautics and Space
Administration.
National Aeronautics and
Space Administration.
ACTION: Notice of Meeting.
AGENCY:
[FR Doc. 2012–27568 Filed 11–9–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Nektar Therapeutics
srobinson on DSK4SPTVN1PROD with
By Notice dated July 17, 2012, and
published in the Federal Register on
July 26, 2012, 77 FR 43862, Nektar
Therapeutics, 1112 Church Street,
Huntsville, Alabama 35801, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Fentanyl (9801), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance in
support of product development.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Nektar Therapeutics to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Nektar
Therapeutics to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and review of the company’s
background and history. Therefore,
pursuant to 21 U.S.C. 823(a), and in
accordance with 21 CFR 1301.33, the
above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–27567 Filed 11–9–12; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:08 Nov 09, 2012
In accordance with the
Federal Advisory Committee Act, Public
Law 92–463, as amended, the National
Aeronautics and Space Administration
announces a meeting of the Audit,
Finance and Analysis Committee of the
NASA Advisory Council.
DATES: Monday, November 26, 2012,
9:00 a.m.–5:15 p.m., Local Time.
ADDRESS: NASA Headquarters. 300 E
Street SW., Conference Room 8E40,
Washington DC 20546.
FOR FURTHER INFORMATION CONTACT: Ms.
Charlene Williams, Office of the Chief
Financial Officer, National Aeronautics
and Space Administration
Headquarters, Washington, DC 20546.
Phone: 202–358–2183.
SUPPLEMENTARY INFORMATION: The
agenda for the meeting includes
briefings on the following topics:
• FY 2012 Financial Statement Audit
• FY 2013 Financial Management
Initiatives
• Administrative Savings
• NASA Budget
• Government Accounting Office
High Risk List
• Financial System Initiative
It is imperative that the meeting be held
on these dates to accommodate the
scheduling priorities of the key
participants. Attendees will be
requested to sign a register and to
comply with NASA security
requirements, including the
presentation of a valid picture ID to
NASA Security before access to NASA
Headquarters. Foreign Nationals
attending this meeting will be required
to provide a copy of their passport and
visa in addition to providing the
following information no later than
November 21, 2012: full name; gender;
date/place of birth; citizenship; visa
information (number, type, expiration
date); passport information (number,
country, expiration date); employer/
affiliation information (name of
institution, address, country,
telephone); title/position of attendee;
and home address to Charlene Williams
at fax: (202) 358–4336. U.S. Citizens and
Permanent Residents (green card
holders) are requested to submit their
name and affiliation 3 working days
SUMMARY:
Jkt 229001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
[FR Doc. 2012–27487 Filed 11–9–12; 8:45 am]
BILLING CODE P
NATIONAL CREDIT UNION
ADMINISTRATION
Sunshine Act; Notice of Agency
Meeting
10:00 a.m., Thursday,
November 15, 2012.
PLACE: Board Room, 7th Floor, Room
7047, 1775 Duke Street, Alexandria, VA
22314–3428.
STATUS: Open.
MATTERS TO BE CONSIDERED: 1. NCUA’s
2013 Operating Budget.
2. NCUA/NCUSIF Overhead Transfer
Rate.
3. Federal Credit Unions’ Operating
Fee Scale.
4. Board Briefing on the Estimated
2013 Premium Ranges for the NCUSIF
and the Corporate Stabilization Fund.
FOR FURTHER INFORMATION CONTACT:
Mary Rupp, Secretary of the Board,
Telephone: 703–518–6304.
TIME AND DATE:
Mary Rupp,
Board Secretary.
[FR Doc. 2012–27648 Filed 11–8–12; 4:15 pm]
BILLING CODE 7535–01–P
NATIONAL SCIENCE FOUNDATION
Astronomy and Astrophysics Advisory
Committee #13883; Notice of Meeting
In accordance with the Federal
Advisory Committee Act (Pub. L. 92–
463, as amended), the National Science
Foundation announces the following
Astronomy and Astrophysics Advisory
Committee (#13883) meeting:
Date and Time: November 30, 2012, 8:30
a.m.–5:00 p.m.; December 1, 2012, 8:30 a.m.–
1:00 p.m.
Place: National Science Foundation, Room
1235, Stafford I Building, 4201 Wilson Blvd.,
Arlington, VA, 22230.
Type of Meeting: Open.
Contact Person: Dr. Jim Ulvestad, Division
Director, Division of Astronomical Sciences,
Suite 1045, National Science Foundation,
4201 Wilson Blvd., Arlington, VA 22230.
Telephone: 703–292–7165.
Purpose of Meeting: To provide advice and
recommendations to the National Science
Foundation (NSF), the National Aeronautics
and Space Administration (NASA) and the
U.S. Department of Energy (DOE) on issues
E:\FR\FM\13NON1.SGM
13NON1
]]>Agencies
[Federal Register Volume 77, Number 219 (Tuesday, November 13, 2012)]
[Notices]
[Page 67677]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27567]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Nektar Therapeutics
By Notice dated July 17, 2012, and published in the Federal
Register on July 26, 2012, 77 FR 43862, Nektar Therapeutics, 1112
Church Street, Huntsville, Alabama 35801, made application by letter to
the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Fentanyl (9801), a basic class of controlled substance
listed in schedule II.
The company plans to manufacture the listed controlled substance in
support of product development.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Nektar Therapeutics to manufacture the listed basic class of controlled
substance is consistent with the public interest at this time. DEA has
investigated Nektar Therapeutics to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems; verification of the company's compliance with state and local
laws; and review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33,
the above named company is granted registration as a bulk manufacturer
of the basic class of controlled substance listed.
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-27567 Filed 11-9-12; 8:45 am]
BILLING CODE 4410-09-P
